-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chronic idiopathic constipation (CIC) and constipated irritable bowel syndrome (IBS-C) are common functional gastrointestinal diseases.
Irritable bowel syndrome
The researchers pooled patients who were randomized to receive plecanatide (3 or 6 mg) or placebo in two CIC and two IBS-C trials.
The pooled intention-to-treat population included 451 patients aged ≥65 years (average age 70 years) and 4364 patients aged <65 years (average age 41.
In summary, the results of this study show that for CIC or IBS-C patients ≥65 years of age, pukanatide is a safe and effective treatment option.
Original source:
Stacy B Menees, et al.
ncbi.
nlm.
nih.
gov/32660770/" target="_blank" rel="noopener">Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older in this message